PMID- 32478631
OWN - NLM
STAT- MEDLINE
DCOM- 20210120
LR  - 20220415
IS  - 1751-2441 (Electronic)
IS  - 1751-2433 (Linking)
VI  - 13
IP  - 6
DP  - 2020 Jun
TI  - Integrating psychotherapy and psychopharmacology: psychedelic-assisted 
      psychotherapy and other combined treatments.
PG  - 655-670
LID - 10.1080/17512433.2020.1772054 [doi]
AB  - INTRODUCTION: Combinations of psychotherapy with antidepressants are 
      gold-standard psychiatric treatments. They operate through complex and 
      interactional mechanisms, not unlike the reemergent paradigm of 
      psychedelic-assisted psychotherapy, which promising research suggests may also be 
      highly effective in even challenging populations. AREAS COVERED: We review the 
      therapeutic mechanisms behind both conventional and psychedelic paradigms, 
      including the evolution of this knowledge and the associated explanatory 
      frameworks. We explore how psychedelics have provided insights about psychiatric 
      illnesses and treatments over the past decades. We discuss limitations to early 
      explanatory models while highlighting and comparing the psychological and 
      biological mechanisms underlying many psychiatric treatments. METHODS: A 
      narrative review was conducted based on a search in Medline/Pubmed up to January 
      1(st), 2020, and iterative retrieval of references from recent reviews and 
      clinical trials. EXPERT OPINION: The contextual model of the common factors of 
      psychotherapy provides a powerful perspective on psychotherapy, antidepressants, 
      and psychedelics, as well as 3,4-methylenedioxymethamphetamine (MDMA) and 
      ketamine. It aligns well with key tenets of psychedelic-assisted psychotherapy. 
      Conventional antidepressants and especially psychedelics may improve the efficacy 
      of psychotherapy via neurochemical changes and increased environmental 
      sensitivity. Combined treatments hold significant promise for advancing the 
      knowledge and treatment of many forms of psychopathology.
FAU - Greenway, Kyle T
AU  - Greenway KT
AUID- ORCID: 0000-0002-7829-493X
AD  - Department of Psychiatry, McGill University , Montreal, Quebec, Canada.
FAU - Garel, Nicolas
AU  - Garel N
AUID- ORCID: 0000-0002-4031-9943
AD  - Department of Psychiatry, McGill University , Montreal, Quebec, Canada.
FAU - Jerome, Lisa
AU  - Jerome L
AUID- ORCID: 0000-0001-6209-8750
AD  - Data Services, MAPS Public Benefit Corporation.
FAU - Feduccia, Allison A
AU  - Feduccia AA
AUID- ORCID: 0000-0002-6918-0738
AD  - Project New Day, Psychedelic.Support.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200601
PL  - England
TA  - Expert Rev Clin Pharmacol
JT  - Expert review of clinical pharmacology
JID - 101278296
RN  - 0 (Hallucinogens)
SB  - IM
MH  - Animals
MH  - Combined Modality Therapy
MH  - Hallucinogens/*administration & dosage
MH  - Humans
MH  - Mental Disorders/physiopathology/*therapy
MH  - Psychotherapy/*methods
OTO - NOTNLM
OT  - Psychedelics
OT  - antidepressants
OT  - ketamine
OT  - ketamine-assisted psychotherapy
OT  - lsd
OT  - mdma
OT  - mdma-assisted psychotherapy
OT  - psilocybin
OT  - psychedelic-assisted psychotherapy
OT  - psychiatry
OT  - psychotherapy
EDAT- 2020/06/02 06:00
MHDA- 2021/01/21 06:00
CRDT- 2020/06/02 06:00
PHST- 2020/06/02 06:00 [pubmed]
PHST- 2021/01/21 06:00 [medline]
PHST- 2020/06/02 06:00 [entrez]
AID - 10.1080/17512433.2020.1772054 [doi]
PST - ppublish
SO  - Expert Rev Clin Pharmacol. 2020 Jun;13(6):655-670. doi: 
      10.1080/17512433.2020.1772054. Epub 2020 Jun 1.